{"component": "definition", "props": {"groups": [{"samples": [{"hash": "8uOJzHOzHTg", "uri": "/contracts/8uOJzHOzHTg#may-compound", "label": "Multi Target Agreement (Immunogen Inc)", "score": 29.3504449008, "published": true}, {"hash": "jQ42BsHSUjC", "uri": "/contracts/jQ42BsHSUjC#may-compound", "label": "Multi Target Agreement (Immunogen Inc)", "score": 26.6290212183, "published": true}, {"hash": "1dOF1noIYvX", "uri": "/contracts/1dOF1noIYvX#may-compound", "label": "Multi Target Agreement (Immunogen Inc)", "score": 26.6290212183, "published": true}], "size": 31, "snippet_links": [{"key": "without-limitation", "type": "clause", "offset": [53, 71]}, {"key": "chemical-synthesis", "type": "definition", "offset": [176, 194]}, {"key": "the-foregoing", "type": "definition", "offset": [297, 310]}, {"key": "each-case", "type": "definition", "offset": [315, 324]}, {"key": "owned-or-controlled", "type": "definition", "offset": [325, 344]}], "snippet": "means any and all maytansinoid compounds (including, without limitation, maytansinol, ansamitocins, DM1 and DM4), whether produced by a botanical source, natural fermentation, chemical synthesis or otherwise, and shall include, without limitation, all variants, fragments or derivatives of any of the foregoing, in each case owned or Controlled by ImmunoGen.", "hash": "75f965b9b754d272a9d417d6e8d84c03", "id": 1}, {"samples": [{"hash": "fu6PntjB8vB", "uri": "/contracts/fu6PntjB8vB#may-compound", "label": "Option and License Agreement (Immunogen Inc)", "score": 22.8288843258, "published": true}, {"hash": "8mGHrkVY72P", "uri": "/contracts/8mGHrkVY72P#may-compound", "label": "Option and License Agreement (Immunogen Inc)", "score": 18.0, "published": true}, {"hash": "44JKHJZ7RfK", "uri": "https://investor.immunogen.com/static-files/c51a8e38-7efb-48bc-bdba-84e55b4579c3", "label": "investor.immunogen.com", "score": 9.9650924025, "published": false}], "size": 5, "snippet_links": [{"key": "without-limitation", "type": "clause", "offset": [53, 71]}, {"key": "chemical-synthesis", "type": "definition", "offset": [175, 193]}, {"key": "the-foregoing", "type": "definition", "offset": [283, 296]}, {"key": "each-case", "type": "definition", "offset": [301, 310]}], "snippet": "means any and all maytansinoid compounds (including, without limitation, maytansine, ansamitocin P-3 and DM1), whether produced by a botanical source, natural fermentation or chemical synthesis, and shall include, without limitation, all variants, fragments or derivatives of any of the foregoing, in each case owned or otherwise Controlled by IMMUNOGEN. May Compounds shall include, without limitation, DM1.", "hash": "c5d56e92560c773df7a9737f1e08c2fd", "id": 2}, {"samples": [{"hash": "7rzthvADl4G", "uri": "/contracts/7rzthvADl4G#may-compound", "label": "License Agreement (Immunogen Inc)", "score": 18.0, "published": true}, {"hash": "4t1C6zxxFck", "uri": "https://investor.immunogen.com/static-files/829f2128-5dbc-47fc-bcae-90bc71314ad8", "label": "investor.immunogen.com", "score": 9.1752224504, "published": false}, {"hash": "fkWDtjDrjOp", "uri": "https://investor.immunogen.com/static-files/76fd4ac6-9222-4c0e-ba5a-cf8b9d260317", "label": "investor.immunogen.com", "score": 9.1752224504, "published": false}], "size": 4, "snippet_links": [{"key": "without-limitation", "type": "clause", "offset": [53, 71]}], "snippet": "means any and all maytansinoid compounds (including, without limitation, maytansine, ansamitocin P-3 and DM1), whether produced by a botanical", "hash": "c2a8f4bf02c14eadd3d9b68846f9e1f4", "id": 3}, {"samples": [{"hash": "hKny2uiGHJA", "uri": "/contracts/hKny2uiGHJA#may-compound", "label": "Collaborative Development and License Agreement (Immunogen Inc)", "score": 27.841889117, "published": true}, {"hash": "2NZsNDksxwU", "uri": "/contracts/2NZsNDksxwU#may-compound", "label": "Collaborative Development and License Agreement (Immunogen Inc)", "score": 21.0, "published": true}], "size": 3, "snippet_links": [{"key": "to-the-extent", "type": "clause", "offset": [105, 118]}, {"key": "including-without-limitation", "type": "clause", "offset": [158, 186]}], "snippet": "means any and all maytansinoid compounds and any and all derivatives of any such maytansinoid compounds, to the extent, in any case, Controlled by ImmunoGen, including without limitation, (a) N2\u2032-deacetyl-N2\u2032-(c-mercapto-1 oxopropyl)-maytansine (CAS No. 139504-50-0) commonly referred to as DM1); (b) N2\u2032-deacetyl-N2\u2032-(4-mercapto-1-oxopentyl)-maytansine (commonly referred as DM3); and (c) N2\u2032-deacetyl-N2\u2032-(4-mercapto-4-methyl-1-oxopentyl)-maytansine (commonly referred as DM4).", "hash": "e9c53639f6c3df23841d8f7f6564f6fd", "id": 4}, {"samples": [{"hash": "3IbwteHUGNP", "uri": "/contracts/3IbwteHUGNP#may-compound", "label": "Exclusive License and Asset Purchase Agreement (Immunogen Inc)", "score": 28.5893223819, "published": true}, {"hash": "aATEP0pv5dT", "uri": "https://investor.immunogen.com/static-files/8d0a022b-a2dc-41fd-9b5c-e544304ed311", "label": "investor.immunogen.com", "score": 7.9952087611, "published": false}], "size": 2, "snippet_links": [{"key": "chemical-synthesis", "type": "definition", "offset": [155, 173]}, {"key": "the-foregoing", "type": "definition", "offset": [255, 268]}, {"key": "each-case", "type": "definition", "offset": [273, 282]}, {"key": "owned-or-controlled", "type": "definition", "offset": [283, 302]}], "snippet": "means any and all maytansinoid compounds (including maytansinol, ansamitocins, DM1 and DM4), whether produced by a botanical source, natural fermentation, chemical synthesis or otherwise, and shall include all variants, fragments or derivatives of any of the foregoing, in each case owned or Controlled by ImmunoGen or any of its Affiliates.", "hash": "7d46dc0421aa4c183dfd290a541e34cc", "id": 5}, {"samples": [{"hash": "5bAGTfXQXqw", "uri": "/contracts/5bAGTfXQXqw#may-compound", "label": "Option and License Agreement (Immunogen Inc)", "score": 21.0, "published": true}, {"hash": "h9FuTPuIyRI", "uri": "https://investor.immunogen.com/static-files/06b520e1-5af1-4a03-963b-34e957cb9249", "label": "investor.immunogen.com", "score": 9.1752224504, "published": false}], "size": 2, "snippet_links": [{"key": "without-limitation", "type": "clause", "offset": [53, 71]}, {"key": "chemical-synthesis", "type": "definition", "offset": [175, 193]}, {"key": "the-foregoing", "type": "definition", "offset": [296, 309]}, {"key": "each-case", "type": "definition", "offset": [314, 323]}], "snippet": "means any and all maytansinoid compounds (including, without limitation, maytansinol, ansamitocins DM1 and DM4), whether produced by a botanical source, natural fermentation, chemical synthesis or otherwise, and shall include, without limitation, all variants, fragments or derivatives of any of the foregoing, in each case controlled by ImmunoGen.", "hash": "ecb95407d581c87db74145a12bf438e6", "id": 6}, {"samples": [{"hash": "9ncxYwdMJTS", "uri": "https://investor.immunogen.com/static-files/5f01dd48-2cac-4ccb-87ed-bc97a934956e", "label": "investor.immunogen.com", "score": 7.1752224504, "published": false}], "size": 2, "snippet_links": [{"key": "without-limitation", "type": "clause", "offset": [53, 71]}], "snippet": "means any and all maytansinoid compounds, including, without limitation (a) N2\u2019-deacetyl-N2\u2019-(3-mercapto-1- oxopropyl)-maytansine (CAS No. 139504-50-0) (commonly referred to as DM1); (b) N2\u2019-deacetyl-N2-(4-mercapto-1-oxopentyl)-maytansine (commonly referred as DM3); and (c) N2\u2019-deacetyl-N2-(4-mercapto-4-methyl-1-oxopentyl)-maytansine (commonly referred as DM4), and all fragments, variants and derivatives of such maytansinoid compounds.", "hash": "088f47013651e10e8190f1cae53198ee", "id": 7}, {"samples": [{"hash": "76pIhWbV5Mb", "uri": "https://investor.immunogen.com/static-files/c8d75981-6b07-4833-aa8d-655cdc027a2a", "label": "investor.immunogen.com", "score": 9.1752224504, "published": false}], "size": 2, "snippet_links": [{"key": "to-the-extent", "type": "clause", "offset": [105, 118]}, {"key": "including-without-limitation", "type": "clause", "offset": [158, 186]}], "snippet": "means any and all maytansinoid compounds and any and all derivatives of any such maytansinoid compounds, to the extent, in any case, Controlled by ImmunoGen, including without limitation, (a) N2\u2032-deacetyl-N2\u2032-(c-mercapto-1 oxopropyl)-maytansine (CAS No. 139504- 50-0) commonly referred to as DM1); (b) N2\u2032-deacetyl-N2\u2032-(4-mercapto-1-oxopentyl)-maytansine (commonly referred as DM3); and (c) N2\u2032-deacetyl-N2\u2032-(4-mercapto-4-methyl-1-oxopentyl)-maytansine (commonly referred as DM4).", "hash": "3c5ea9ffe25634011ff50a19d2015dcd", "id": 8}, {"samples": [{"hash": "8mGHrkVY72P", "uri": "/contracts/8mGHrkVY72P#may-compound", "label": "Option and License Agreement (Immunogen Inc)", "score": 18.0, "published": true}], "size": 2, "snippet_links": [{"key": "without-limitation", "type": "clause", "offset": [53, 71]}, {"key": "chemical-synthesis", "type": "definition", "offset": [175, 193]}, {"key": "the-foregoing", "type": "definition", "offset": [283, 296]}, {"key": "each-case", "type": "definition", "offset": [301, 310]}, {"key": "new-drug-application", "type": "definition", "offset": [433, 453]}, {"key": "united-states-code-of-federal-regulations", "type": "definition", "offset": [485, 526]}, {"key": "as-amended", "type": "definition", "offset": [528, 538]}, {"key": "from-time-to-time", "type": "clause", "offset": [539, 556]}, {"key": "the-fda", "type": "clause", "offset": [569, 576]}, {"key": "regulatory-approval", "type": "clause", "offset": [585, 604]}, {"key": "licensed-product", "type": "clause", "offset": [628, 644]}, {"key": "in-the-united-states", "type": "clause", "offset": [645, 665]}, {"key": "the-field", "type": "definition", "offset": [701, 710]}], "snippet": "means any and all maytansinoid compounds (including, without limitation, maytansine, ansamitocin P-3 and DM1), whether produced by a botanical source, natural fermentation or chemical synthesis, and shall include, without limitation, all variants, fragments or derivatives of any of the foregoing, in each case owned or otherwise Controlled by IMMUNOGEN. May Compounds shall include, without limitation, DM1. 1.26 \"NDA\" shall mean a new drug application (as defined in Title 21 of the United States Code of Federal Regulations, as amended from time to time) filed with the FDA seeking Regulatory Approval to market and sell any Licensed Product in the United States for a particular indication within the Field.", "hash": "ced15a0a6d7c35047f63f01f34638275", "id": 9}, {"samples": [{"hash": "i2vV8XpaPhY", "uri": "/contracts/i2vV8XpaPhY#may-compound", "label": "Development and License Agreement (Immunogen Inc)", "score": 21.0, "published": true}], "size": 2, "snippet_links": [{"key": "without-limitation", "type": "clause", "offset": [53, 71]}], "snippet": "means any and all maytansinoid compounds, including, without limitation (a) N2\u2019-deacetyl-N2\u2019-(3-mercapto-1-oxopropyl)-maytansine (CAS No. 139504-50-0) (commonly referred to as DM1); (b) N2\u2019-deacetyl-N2-(4-mercapto-1-oxopentyl)-maytansine (commonly referred as DM3); and (c) N2\u2019-deacetyl-N2-(4-mercapto-4-methyl-1-oxopentyl)-maytansine (commonly referred as DM4), and all fragments, variants and derivatives of such maytansinoid compounds.", "hash": "7a3eff565f840180c485aebdc82260c8", "id": 10}], "next_curs": "ClkSU2oVc35sYXdpbnNpZGVyY29udHJhY3RzcjULEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIVbWF5LWNvbXBvdW5kIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"size": 47, "title": "MAY Compound", "snippet": "means any and all maytansinoid compounds (including, without limitation, maytansinol, ansamitocins, DM1 and DM4), whether produced by a botanical source, natural fermentation, chemical synthesis or otherwise, and shall include, without limitation, all variants, fragments or derivatives of any of the foregoing, in each case owned or Controlled by ImmunoGen.", "id": "may-compound", "examples": ["Notwithstanding the foregoing, Novartis shall promptly notify ImmunoGen whenever Novartis or an Affiliate or Sublicensee has, directly or indirectly, engaged any Third Party to provide any <strong>MAY Compound</strong> for use, or potential use, in the manufacture of any Licensed Product or any of its components.", "Lilly shall order all amounts of <strong>MAY Compound</strong>, and ImmunoGen shall use commercially reasonable efforts to deliver all such ordered amounts, in accordance with forecasting parameters, advance ordering timeframes and delivery timeframes and specifications to be agreed upon by the Parties.", "In connection with such supply pursuant to this Section 4.2, Lilly hereby agrees that (a) it shall not use the <strong>MAY Compound</strong> in any human subject; and (b) it shall use the <strong>MAY Compound</strong> in compliance with all Applicable Laws.", "ImmunoGen shall charge, and Lilly agrees to pay, [***] for such <strong>MAY Compound</strong>.", "Notwithstanding the foregoing, Lilly shall promptly notify ImmunoGen whenever Lilly has, directly or indirectly, engaged any Permitted Third Party Service Provider to provide any <strong>MAY Compound</strong> for use, or potential use, in the manufacture of any Licensed Product or any of its components.", "Lilly shall be entitled to transfer <strong>MAY Compound</strong> to any Affiliate, Sublicensee or Permitted Third Party Service Provider under terms obligating such Affiliate, Sublicensee or Permitted Third Party Service Provider not to transfer or use such <strong>MAY Compound</strong> except in compliance with the preceding sentence.", "ImmunoGen will also provide relevant free <strong>MAY Compound</strong> and anti-maytansine Antibody to Novartis for biological and analytical research; provided that ImmunoGen will provide [***] and [***] at [***] with respect to the overall Research Program, with additional amounts of the foregoing to be provided at ImmunoGen\u2019s established standard pricing as consistently applied by ImmunoGen, as reasonably determined to be necessary by the JRC for Novartis to complete such biological research and analytical research.", "Subject to Section 5.1.5(b)(i), within [***] ([***]) days of the end of each Calendar Quarter following the exercise by ImmunoGen of a Co-Development Option pursuant to Section 5.1.1(a), Biotest shall pay the applicable Pivotal <strong>MAY Compound</strong> Process Development Percentage of the Pivotal <strong>MAY Compound</strong> Process Development Costs incurred over such Calendar Quarter using a method of allocation to be determined by the JFC in good faith, based on the method of allocation described in Section 5.1.5(b)(i) above.", "Within [***] ([***]) days of the exercise by ImmunoGen of a Co-Development Option pursuant to Section 5.1.1(a), ImmunoGen shall provide Biotest with a reasonably detailed written accounting of the Pivotal <strong>MAY Compound</strong> Process Development Costs incurred through the date of exercise of the Co-Development Option and the applicable Pivotal <strong>MAY Compound</strong> Process Development Percentage.", "At each meeting of the JDC the Parties shall update the JDC as to such Pivotal <strong>MAY Compound</strong> Process Development Costs incurred through the date of such JDC meeting."], "related": [["exempt-compound", "Exempt compound", "Exempt compound"], ["collaboration-compound", "Collaboration Compound", "Collaboration Compound"], ["back-up-compound", "Back-Up Compound", "Back-Up Compound"], ["licensed-compound", "Licensed Compound", "Licensed Compound"], ["licensed-compounds", "Licensed Compounds", "Licensed Compounds"]], "related_snippets": [], "updated": "2025-07-06T21:56:50+00:00"}, "json": true, "cursor": ""}}